• Explore /
  • Poster
  • / Phase 1b/2, open-label, dose-escalation and expansion trial of tucatinib in combination with trastuzumab with and without oxaliplatin-based chemotherapy or pembrolizumab in patients with unresectable or metastatic HER2+ gastrointestinal cancers (trial in progress).

Phase 1b/2, open-label, dose-escalation and expansion trial of tucatinib in combination with trastuzumab with and without oxaliplatin-based chemotherapy or pembrolizumab in patients with unresectable or metastatic HER2+ gastrointestinal cancers (trial in progress).

Abstract Video & Slides Poster

Authors

null

Haeseong Park

Washington University School of Medicine, St. Louis, MO

Haeseong Park , Tanios S. Bekaii-Saab , Sunnie S. Kim , Suneel Deepak Kamath , Michael J. Pishvaian , Christopher Chen , David Bing Zhen , Joal Garrido Mayor , Qianwen Tan , John H. Strickler

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04430738

DOI

10.1200/JCO.2022.40.4_suppl.TPS376

Abstract #

TPS376

Poster Bd #

M8

Abstract Disclosures

Similar Posters

First Author: Samuel J Klempner

First Author: Lin Shen

First Author: Manish A. Shah

First Author: John H. Strickler